摘要
糖尿病前期(脾瘅)是2型糖尿病发生的重要环节,包含空腹血糖受损和糖耐量异常。糖尿病前期患病率呈高速增长态势,如不采取干预措施,在4~7 a内有15%人群发展成为糖尿病。中西医药物治疗糖尿病前期被越发引起重视。西医药物治疗包含二甲双胍、α-葡萄糖苷酶抑制剂、噻唑烷二酮类、二肽基肽酶Ⅳ(DPP-4)抑制剂、胰高血糖素样肽-1(GLP-1)受体激动剂等。中医从脏腑理论、气血津液、阴阳虚损等多角度辨证论治。文章主要从以上方面综述糖尿病前期相关中西医药物研究进展。
Pre-diabetes(spleen pyretic abundance) is an important part of type 2 diabetes,including impaired fasting glucose and impaired glucose tolerance. The pre-diabetes prevalence rate is growing rapidly,if no intervention measures are taken,15% of the population develops into diabetes within 4-7 years. Chinese and Western medicines have become more and more important in the treatment of pre-diabetes. Western medicine treatment includes metformin,α-glucosidase inhibitor,thiazolidinedione,dipeptidyl peptidase IV(DPP-4) inhibitor,glucagon like pep Tide-1,(GLP-1) receptor agonists and so on. Traditional Chinese medicine treats and treats from the perspectives of viscera theory,qi and blood fluid,yin and yang deficiency. This article mainly reviews the progress of prediabetes related Chinese and Western medicine research from the above aspects.
作者
刘妍
常丽萍
高怀林
LIU Yan;CHANG Liping;GAO Huailin(Hebei University of Chinese Medicine,Shijiazhuang 050091,China;State Key Laboratory of Collateral Disease Research and Innovation of Traditional Chinese Medicine,Shijiazhuang Yiling Pharmaceutical,Shijiazhuang 050035,China;Hebei Key Laboratory of Collateral Disease,Key Laboratory of State Administration of Traditional Chinese Medicine,Hebei Yiling Medical Research Institute,Shijiazhuang 050035,China;Hebei Yiling Hospital,State Administration of Traditional Chinese Medicine,TCM Collaterology Key Discipline,Shijiazhuang 050091,China)
出处
《天津中医药》
CAS
2019年第11期1141-1144,共4页
Tianjin Journal of Traditional Chinese Medicine
基金
国家重点研发计划重点专项资助项目(2017YFC1700501)
河北省重点研发计划(18277763D)
河北省中医药管理局科研计划课题(2018200)
北京市科技计划课题(Z181100001918015)
关键词
糖尿病前期
脾瘅
药物治疗
pre-diabetes
spleen pyretic abundance
drug therapy
